Interlaboratory comparison study of the Colony Forming Efficiency assay for assessing cytotoxicity of nanomaterials

Nanotechnology has gained importance in the past years as it provides opportunities for industrial growth and innovation. However, the increasing use of manufactured nanomaterials (NMs) in a number of commercial applications and consumer products raises also safety concerns and questions regarding potential unintended risks to humans and the environment. Since several years the European Commission’s Joint Research Centre (JRC) is putting effort in the development, optimisation and harmonisation of in vitro test methods suitable for screening and hazard assessment of NMs. Work is done in collaboration with international partners, in particular the Organisation for Economic Co-operation and Development (OECD). This report presents the results from an interlaboratory comparison study of the in vitro Colony Forming Efficiency (CFE) cytotoxicity assay performed in the frame of OECD's Working Party of Manufactured Nanomaterials (WPMN). Twelve laboratories from European Commission, France, Italy, Japan, Poland, Republic of Korea, South Africa and Switzerland participated in the study coordinated by JRC. The results show that the CFE assay is a suitable and robust in vitro method to assess cytotoxicity of NMs. The assay protocol is well defined and is easily and reliably transferable to other laboratories. The results obtained show good intra and interlaboratory reproducibility of the assay for both the positive control and the tested nanomaterials. In conclusion the CFE assay can be recommended as a building block of an in vitro testing battery for NMs toxicity assessment. It could be used as a first choice method to define dose-effect relationships for other in vitro assays.JRC.I.4-Nanobioscience

Comprehensive early intervention for patients with first-episode psychosis in Japan (J-CAP): study protocol for a randomised controlled trial

<p>Abstract</p> <p>Introduction</p> <p>Comprehensive approaches for patients with psychotic symptoms play essential roles in the symptomatic and functional outcomes of patients, especially during disease onset. In Japan, the shortage of mental health services, particularly for outpatients, and community-based supports has been a major problem. The purpose of this trial is to investigate the effectiveness and affordability of 18-month comprehensive early intervention services for patients with first-episode psychosis compared with typical treatment.</p> <p>Methods</p> <p>This interventional, parallel, single-blinded (open but blinded raters trial) was effectively designed. The participants are patients with a diagnosis of F2 or F3 (International Classification of Disease, 10 th revision), with psychotic symptoms. The inclusion criteria were an age of 15-35 years, onset of psychotic symptoms within 5 years, first-episode psychosis, and residence in the catchment area of each site. Allocation will be conducted equally between case management and standard care groups. After enrollment, standard care will be provided for both groups, and community-based care to promote recovery for 18 months will be provided for the comprehensive approach group. The primary outcome will be the function domain of the global assessment of functioning scores at 18 months after enrollment. Data assessment will be performed at enrollment and 18, 36, and 60 months after enrollment. The target sample size will be 150, and registration will occur from March 1, 2011, to September 30, 2012.</p> <p>Discussion</p> <p>This trial will provide promising results about the effectiveness and cost-effectiveness of early intervention services in Japan to improve the quality and quantity of community mental health services.</p> <p>Trial registration</p> <p>This trial was registered in The University Hospital Medical Information Network Clinical Trials Registry (No. UMIN000005092).</p

EGUIDE project and treatment guidelines

Aim: Although treatment guidelines for pharmacological therapy for schizophrenia and major depressive disorder have been issued by the Japanese Societies of Neuropsychopharmacology and Mood Disorders, these guidelines have not been well applied by psychiatrists throughout the nation. To address this issue, we developed the ‘Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)’ integrated education programs for psychiatrists to disseminate the clinical guidelines. Additionally, we conducted a systematic efficacy evaluation of the programs. Methods: Four hundred thirteen out of 461 psychiatrists attended two 1‐day educational programs based on the treatment guidelines for schizophrenia and major depressive disorder from October 2016 to March 2018. We measured the participants’ clinical knowledge of the treatment guidelines using self‐completed questionnaires administered before and after the program to assess the effectiveness of the programs for improving knowledge. We also examined the relation between the participants’ demographics and their clinical knowledge scores. Results: The clinical knowledge scores for both guidelines were significantly improved after the program. There was no correlation between clinical knowledge and participant demographics for the program on schizophrenia; however, a weak positive correlation was found between clinical knowledge and the years of professional experience for the program on major depressive disorder. Conclusion: Our results provide evidence that educational programs on the clinical practices recommended in guidelines for schizophrenia and major depressive disorder might effectively improve participants’ clinical knowledge of the guidelines. These data are encouraging to facilitate the standardization of clinical practices for psychiatric disorders

糖尿病とがんを併せ持つ患者のがん治療中のセルフマネジメントの実際

Objective: To describe the state of self-management during cancer treatment in patients with diabetes and cancer.Methods: Patients with diabetes and cancer who visited the diabetes outpatient clinic of general hospitals in Japan were recruited as participants. Data were collected in interviews using a semi-structured questionnaire and were analyzed qualitatively and inductively using content analysis.Results: Two categories and six subcategories of self-management for cancer treatment were revealed. The categories included “adhering to blood glucose management for cancer treatment” and “getting into shape for cancer treatment” and the subcategories included “remembering to measure blood glucose,” “thorough glycemic control through drug therapy,” “ensuring glycemic control through exercise therapy,” “addressing adverse events of anticancer drugs,” “reconsidering tobacco and alcohol consumption in the wake of cancer,” and “performing indicated rehabilitation.”Two categories and three subcategories of self-management for diabetes treatment were revealed. The categories included “continuing a diabetes treatment lifestyle true to oneself” and “judging the state of diabetes,” and the subcategories included “eating a diet that does not aggravate diabetes,” “continuing self-management without overdoing it,” and “estimating whether blood sugar levels are high or low.”Discussion: It was revealed that patients were self-managing both cancer and diabetes, suggesting the need for information sharing and collaboration between cancer and diabetic nurses.論

A Randomized Controlled Trial of Comprehensive Early Intervention Care in Patients with First-Episode Psychosis in Japan: 1.5-year Outcomes from the J-CAP Study

The first episode of psychosis represents a critical period wherein comprehensive early intervention in psychosis (EIP) may alter the course of illness. However, evidence from randomized controlled trials that have examined the impact of comprehensive EIP care on clinical and functional recovery assessed by independent blinded raters is limited. The objective of this study was to conduct a single-blinded multicenter trial comparing comprehensive EIP care and standard care in young patients with first-episode psychosis (FEP) in Japan (J-CAP Study). A total of 77 participants with FEP (aged 15–35 years) were randomized to receive standard care or specialized comprehensive EIP care and were followed up for 1.5 years (trial no.: UMIN000005092). Function (measured with the Global Assessment of Functioning) and clinical remission (defined by internationally standardized criteria proposed by the Remission in Schizophrenia Working Group) were evaluated by independent raters who were blinded to group assignment. Dropout rate and other secondary outcomes were also examined. The specialized EIP care group had a higher clinical remission rate (odds ratio, 6.3; 95% confidence interval, 1.0–37.9) and lower treatment dropout rate (odds ratio, 0.038; 95% confidence interval, 0.002–0.923) than the standard care group, even after adjusting for baseline characteristics. Functional improvement in the specialized EIP care group was slightly higher than that in the standard care group, but this difference was not statistically significant (p = 0.195). From the results, we conclude that comprehensive EIP care may provide advantages over standard care in patients with FEP

Relatório de estágio em farmácia comunitária

Relatório de estágio realizado no âmbito do Mestrado Integrado em Ciências Farmacêuticas, apresentado à Faculdade de Farmácia da Universidade de Coimbr

Complete coding sequences of cDNAs of four variants of rabbit skeletal muscle troponin T

Four variants of troponin T (TnT) cDNAs have been isolated and sequenced. These cDNAs have been derived from rabbit skeletal muscle, the most widely studied source of troponin, of a 11-day-old animal. One variant (TnT-1) contains the complete coding sequence, while in three variants the coding sequences are truncated at the 5′ termini. The previously published amino acid sequence differs from the present cDNA-derived sequences at three locations. At least two, possibly all, of them are probably accounted for by errors in peptide sequencing. The present results are consistent with the two types of alternative splicing of TnT genes, both being first reported on the rat gene. (1) Highly variable sequences in the amino-terminal region are accounted for by the alternative splicing of exons 4–8 in an interchangeable but not mutually exclusive manner. (2) In the carboxyl-terminal region, the alternative splicing of two exons 17 (β-type) or 16 (α-type) in mutually exclusive manner is consistent with the difference between all the four cDNAs, which express exon 17, and the previously published peptide sequence (derived from the adult muscle) in which exon 16 is present. This variation also corresponds to the finding in chicken skeletal muscle that the choice of exon 16 or 17 may be dependent on developmental stages. Finally, a sequence is observed corresponding to an extra exon or exons between exons 5 and 6. This sequence is shorter than that of the chicken skeletal muscle gene and is not detected in the rat skeletal muscle gene

Reconstitution of Rabbit Skeletal Muscle Troponin from the Recombinant Subunits All Expressed in and Purified from E. coli

Three subunits of rabbit skeletal muscle troponin were expressed in and purified from Escherichia coli. The procedures were optimized, and the reconstituted troponin complex is highly homogeneous, stable, and obtainable in large quantities, allowing us to conduct crystallization studies of the troponin complex. The three subunits expressed and purified are β-TnT(N'–208), TnI(C64A, C133S), and the wild type TnC. β–TnT(N'–208) is a 25 kDa fragment of y9-troponin T, which consists of 208 amino acids and lacks 58 residues in the N–terminal variable region. TnI(C64A, C133S) is a mutant troponin I, in which Cys–64 and Cys–133 are replaced by Ala and Ser, respectively. Each subunit was separately expressed in E. coli, purified by column chromatography including HPLC, and reassembled to form troponin complex. The reconstituted troponin complex was not distinguishable from authentic troponin prepared from rabbit skeletal muscle; the acto-Sl ATPase rate, as well as the superprecipitation, was calcium-sensitive. Small flat crystals up to 0.2 mm long have been reproducibly obtained in preliminary crystallization trials

Emergence of a colistin-resistant Escherichia coli clinical isolate harboring mcr-1 in Japan

The mcr-1 is a gene encoding a phosphoethanolamine transferase, which confers resistance to colistin by transferring phosphoethanolamine to lipid A. We describe here the emergence of a colistin-resistant Escherichia coli clinical isolate harboring plasmid-mediated mcr-1 in Japan. The isolate belonged to ST5702 and is suspected to come from livestock and transmitted to human. This is the first report of a clinical isolate harboring mcr-1 in Japan